<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00199732</url>
  </required_header>
  <id_info>
    <org_study_id>I04002</org_study_id>
    <nct_id>NCT00199732</nct_id>
  </id_info>
  <brief_title>Evaluation of cccDNA and Total HBV DNA Kinetics in Lymphocytes, Total Blood and Serum in Chronic Hepatitis B Patients Treated With Adefovir Dipivoxil and Peg Interferon Alpha 2a</brief_title>
  <acronym>DNA-EVAL</acronym>
  <official_title>Evaluation of cccDNA and Total HBV DNA Kinetics in Lymphocytes, Total Blood and Serum in Chronic Hepatitis B Patients Treated With Adefovir Dipivoxil and Peg Interferon Alpha 2a</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Serum HBV DNA is a referent but insufficient marker of therapeutic follow-up in chronic
      hepatitis B treatment. Intra hepatic cccDNA disappearance reflects HBV eradication in the
      liver.

      Intra lymphocyte cccDNA could be a new marker of HBV eradication after treatment.

      The major interest of this marker is that it can be measured by a simple blood test instead
      of a liver biopsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      - Studying intra lymphocyte and blood cccDNA: before inclusions, D0 then each month during
      the first three months each three months during treatment and follow-up.

      - Viral kinetics:Before inclusions, at D0, then monthly till the end of treatment and
      follow-up: Evolution of quantitative viraemia in serum Evolution of quantitative viraemia in
      circulating lymphocytes Evolution of quantitative viraemia in total blood

      - Studying viral genotypes
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Kinetic cccDNA</measure>
    <time_frame>6 months</time_frame>
    <description>Studying the kinetics of cccDNA in cells and whole blood</description>
  </primary_outcome>
  <enrollment type="Actual">19</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic hepatitis B infection and treated with adefovir dipivoxil and peg
        interferon alpha 2a.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients &gt;18 years of age and &lt;70 years of age

          -  Patients AgHbs+ and AgHbe+ or AgHbe-, and B viral DNA &gt;104 copies/ml PCR COBAS MONITOR

          -  Patients treated with adefovir dipivoxil and peg interferon alpha 2a

          -  Chronic liver disease consistent with chronic hepatitis B infection on a biopsy
             obtained within the past 24 months

          -  Naïve patients or patients having a relapse or a therapeutic failure after monotherapy
             lamivudine or interferon, or bitherapy interferon alpha-lamivudine

        Exclusion Criteria:

          -  Co-infection HIV, HCV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Véronique Loustaud-Ratti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Limoges</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service d'Hépato-gastroentérologie</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Interne</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Virologie</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et Tropicales</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>April 16, 2013</last_update_submitted>
  <last_update_submitted_qc>April 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic hepatitis B</keyword>
  <keyword>CCC DNA kinetics</keyword>
  <keyword>Total HBV DNA kinetics</keyword>
  <keyword>Adefovir-Dipovixil</keyword>
  <keyword>Peg interferon alpha 2a</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

